市場調查報告書

血管運動神經症狀:市場分析,流行病學,市場預測 (2030年)

Vasomotor Symptoms - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 968102
出版日期 內容資訊 英文 168 Pages
商品交期: 最快1-2個工作天內
價格
血管運動神經症狀:市場分析,流行病學,市場預測 (2030年) Vasomotor Symptoms - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年10月30日內容資訊: 英文 168 Pages
簡介

全球主要7個國家的更年期的血管運動神經症狀 (發熱/盜汗)的患者數,2017年時刻達到了總合4109萬6968人。還有同年的市場規模成為17億7580萬美元。

本報告提供全球主要7個國家 - 美國,歐洲主要5個國家 (EU5:法國、德國、義大利、西班牙、英國),日本 - 的血管運動神經症狀 (發熱/盜汗)的疫情趨勢與今後的市場預測相關分析,疾病概要和市場基本結構,目前治療方法和未滿足需求,患病人數趨勢預測,已上市/臨床實驗中的治療藥的簡介,全球整體/各國的市場規模 (過去3年、今後11年份),主要的推動及阻礙市場要素等資訊彙整,為您概述為以下內容。

目錄

第1章 主要考察

第2章 血管運動神經症狀 (發熱/盜汗):市場概要

  • 整體市場佔有率結構 (2017年)
  • 整體市場佔有率結構 (2030年)

第3章 摘要整理

第4章 組織

第5章 流行病學與市場分析方法

第6章 更年期的血管運動神經症狀 (VMS):疾病的背景情況和概要

  • 簡介
  • 血管運動神經症狀 (發熱/盜汗)
  • VMS的徵兆與症狀
  • VMS的病理生理學
  • VMS的危險因素
  • VMS的效果
  • 早期閉經
  • 奶癌治療伴隨的更年期障礙

第7章 流行病學和患者人口

  • 主要的分析結果

第8章 主要7個國家的更年期的血管運動神經症狀 (發熱/盜汗)的患病者總數

第9章 更年期的血管運動神經症狀的流行病學:各國分析

  • 美國
    • 假設和理論的根據
    • 更年期的血管運動神經症狀 (發熱/盜汗)的患病者總數
    • 更年期的血管運動神經症狀的患病人數:各重症度
  • (EU5歐洲主要5個國家)
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第10章 治療流程,目前治療、診療方法

  • 荷爾蒙療法
    • 雌激素補充療法
    • 孕酮劑
  • 對於血管運動神經症狀的非荷爾蒙性藥物療法
    • Clonidine
    • SSRI(血清素再吸收抑制劑)
    • Gabapentin
    • 行為轉換
  • 補充、替代療法(CAM)

第11章 未滿足需求

第12章 成藥:各類藥物

  • 荷爾蒙療法
    • 雌激素單獨療法
    • 聯合治療
  • 非荷爾蒙療法
    • 核准醫藥品
    • 抗憂鬱症藥(不適用)
  • 近幾年已批准荷爾蒙治療藥
  • Bijuva:TherapeuticsMD
    • 藥物的說明
    • 法規的里程碑
    • 其他開發活動
    • 臨床開發
    • 臨床實驗資訊
    • 安全性和有效性
    • 產品簡介

第12章 新治療藥

  • 主要產品一覽
  • 荷爾蒙為基礎的治療方法
  • Donesta:Mithra Pharmaceuticals(Donesta Biosciences)
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • 非荷爾蒙為基礎的治療方法
  • NT-814:KaNDy Therapeutics
  • FP-101:Fervent Pharmaceuticals
  • Fezolinetant: Astellas Pharma
  • 其他的潛在治療方法
  • SJX 653:Sojournix
  • MT-8554:田邊三菱製藥

第14章 血管運動神經症狀:主要7個國家的市場分析

  • 主要調查結果
  • 更年期血管運動神經症狀的市場規模:主要7個國家

第15章 主要7個國家:市場未來展望

  • 美國的市場規模
    • 更年期血管運動神經症狀的整體市場規模
    • 市場規模:各治療藥物
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第16章 推動市場要素

第17章 市場阻礙因素

第18章 SWOT分析

第19章 案例研究

  • 病例報告:更年期障礙的認識的血管運動神經症狀
  • 病例報告:荷爾蒙療法(HT)突然中止的症候性患者

第20章 產業的專家 (KOL)的見解

第21章 附錄

第22章 DelveInsight的服務內容

第23章 免責聲明

第24章 關於DelveInsight

目錄
Product Code: DIMI0802

DelveInsight's 'Vasomotor symptoms (Hot flashes/Night sweats)-Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the Vasomotor symptoms including Hot flashes or night sweats, historical and forecasted epidemiology as well as the Vasomotor symptoms (Hot flashes/Night sweats) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The Vasomotor symptoms (Hot flashes/Night sweats) market report provides current treatment practices, emerging drugs for Hot flashes/Night sweats and their market share of the individual therapies, current and forecasted Vasomotor symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current vasomotor symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Vasomotor symptoms (Hot flashes/Night sweats) Disease Understanding and Treatment Algorithm

Vasomotor symptoms (Hot flashes/Night sweats) Overview

Vasomotor symptoms are one of the major symptoms of menopause that principally include hot flashes (HF) and night sweats (NS) and occur in most women across the globe. A woman with VMS experiences abundant heat accompanied by sweating and flushing, especially around the head, neck, chest, and upper back region. These are the menopausal symptoms for which women seek treatment during menopause most often. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones. Normally, core body temperature (CBT) remains within a specific range, oscillating with daily circadian rhythms.

Menopause is characterized by physiologic and psychosocial changes in a woman's life. VMS, and the sleep and mood disturbances that often result from these, can significantly negatively impact the overall quality of life (QOL) for a substantial number of women. VMS's impact has gained in importance as the lifespan of women has increased throughout the world since women can expect to spend a significant portion of their lives after menopause. Maintenance of functional ability and a good QOL is of utmost importance. Given the prevalence and duration of VMS among midlife women, it is critical to understand the underlying biology of this symptom, the extent to which VMS may impair QOL, and whether VMS may serve as a marker for other important health conditions. VMS experienced in up to 80% of menopausal women; prevalence depends on region. The vasomotor symptoms may range in severity from discomfort to debilitation; more than half of the women with VMS experience "moderate to severe" symptoms.

Hot flashes, the hallmark symptom of menopause, have been implicated in night sweats, sleep disturbances, cognitive and mood disorders, and increase dependence on medications, impairing the quality of life. The average duration of vasomotor symptoms is 7 years and may range in severity from discomfort to debilitation. Increasing stress levels may lead to a hormonal imbalance and early menopause. Changes in dietary habits, stress, and lifestyle globally changed the demand for menopausal solutions in the market.

Vasomotor symptoms (Hot flashes/Night sweats) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Vasomotor symptoms (Hot flashes/Night sweats) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Vasomotor symptoms (Hot flashes/Night sweats) market report give a thorough understanding of Vasomotor symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Vasomotor symptoms of treatment algorithms and treatment guidelines for Vasomotor symptoms in the US, Europe, and Japan.

Both the US (ACOG) and EU (NICE) guidelines recommend systemic hormone replacement therapy (HRT) as the most effective therapy for VMS related to menopause. These include estradiol, conjugated estrogen, selective estrogen receptor modulators (SERMs), and compounded or synthetic hormones. Non-hormonal agents such as SSRIs are recommended as alternatives for patients with contraindications to HRT.

Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology

The Vasomotor symptoms epidemiology division provides insights about the historical and current patient pool of Hot flashes/Night sweats and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total diagnosed prevalent cases of vasomotor symptoms (Hot flashes/Night sweats) patients were found to be more in postmenopausal women aged 40-65 years in 7MM during the study period, i.e., 2017-2030. The International Menopause Society (IMS) Council of Affiliated Menopause Societies (CAMS) have collaborated in studies to compare the prevalence of HFs in different climates, continents, and at different altitudes.

The disease epidemiology covered in the report provides historical as well as forecasted vasomotor symptoms epidemiology segmented as the prevalence of Vasomotor symptoms, Prevalent Cases of Hot Flashes associated with Post Menopause, Severity-specific cases of Hot flashes (Mild, Moderate, and Severe) in post-menopause, and Diagnosed and Treatable Cases of Vasomotor symptoms. The report includes the prevalent scenario of Vasomotor symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology

The epidemiology segment also provides the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Vasomotor Symptoms Associated with post-menopause in 7MM countries was 41,096,968 in 2017.

Vasomotor symptoms (Hot flashes/Night sweats) Drug Chapters

The drug chapter segment of the Vasomotor symptoms (Hot flashes/Night sweats) report encloses the detailed analysis of Hot flashes marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Vasomotor symptoms (Hot flashes/Night sweats), clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Vasomotor symptoms (Hot flashes/Night sweats) Marketed Drugs

Bijuva: TherapeuticsMD

Bijuva (estradiol and progesterone) is a registered trademark of TherapeuticsMD and is a novel combination of 17B-estradiol and progesterone developed using SYMBODA technology. It is the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule and indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause. It was approved in October 2018 and launched in April 2019.

Products detail in the report…

Vasomotor symptoms (Hot flashes/Night sweats) Emerging Drugs

NT-814: KaNDy Therapeutics

NT-814 is a first in class, orally-administered, potent, and selective dual antagonist of both the neurokinin-1 and 3 receptors under development by KaNDy Therapeutics as a therapy for a range of Women's Health conditions. It addresses VMS by modulating a group of estrogen-sensitive neurons in the hypothalamus in the brain called the kisspeptin-neurokinin B-dynorphin-KNDy neurons. NT-814 has successfully completed Phase IIa and IIb studies demonstrating the potential to reduce the frequency and severity of hot flashes and night sweats (called vasomotor symptoms) of the menopause. Now it is planning to progress to enter Phase III study in this anchor indication.

Products detail in the report…

Vasomotor symptoms (Hot flashes/Night sweats) Market Outlook

The Vasomotor symptoms (Hot flashes/Night sweats) market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted Vasomotor symptoms (Hot flashes/Night sweats) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Vasomotor symptoms (Hot flashes/Night sweats) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Vasomotor symptoms (Hot flashes/Night sweats) market in 7MM is expected to change in the study period 2017-2030.

The current therapeutic landscape in the 7MM can be divided into two major categories based on the class of drugs such as Hormonal Therapies and Nonhormonal Therapy. Systemic hormone replacement therapy, with estrogen alone or in combination with a progestin, is the most effective therapy for vasomotor symptoms related to menopause.

Hormone therapy (HT) consists of estrogen-only therapy or combined-estrogen-progestogen therapy. The former is the most common form of treatment for menopausal symptoms and effective in relieving vasomotor symptoms. At present, there are almost 100 different combinations of estrogen-only, progestin, and combination hormone therapies available. These can be given orally or transdermally through a patch, spray, or gel. Oral and transdermal estrogens are equally beneficial for the treatment of vasomotor symptoms.

Key Findings

This section includes a glimpse of the Vasomotor symptoms (Hot flashes/Night sweats) market in 7MM. The market size of Hot Flashes Associated with Post-Menopause in the seven major markets was USD 1,775.80 million in 2017.

The United States Market Outlook

This section provides the total Vasomotor symptoms (Hot flashes/Night sweats) market Size and market Size by therapies in the United States.

The United States accounts for the highest market size of Hot Flashes associated with Post menopause compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Vasomotor symptoms (Hot flashes/Night sweats) market Size and market Size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Owing to the adverse events observed by the use of Hormonal therapy, the patient share is declining over the year. Consequently, the market share is expected to decrease for Hormonal therapies during the forecast period [2020-2030]

Japan Market Outlook

The total Vasomotor symptoms (Hot flashes/Night sweats) market Size and market Size by therapies in Japan are also mentioned.

Vasomotor symptoms (Hot flashes/Night sweats) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Vasomotor symptoms (Hot flashes/Night sweats), market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Vasomotor symptoms (Hot flashes/Night sweats) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Vasomotor symptoms (Hot flashes/Night sweats) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Vasomotor symptoms (Hot flashes/Night sweats) emerging therapies.

Reimbursement Scenario in Vasomotor Symptoms

Approaching reimbursement proactively can positively impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Vasomotor symptoms (Hot flashes/Night sweats) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Vasomotor symptoms (Hot flashes/Night sweats) market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Vasomotor symptoms (Hot flashes/Night sweats) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Vasomotor symptoms, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Vasomotor symptoms (Hot flashes/Night sweats) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Vasomotor symptoms (Hot flashes/Night sweats) market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Vasomotor symptoms (Hot flashes/Night sweats) market.

Report Highlights:

  • In the coming years, Vasomotor symptoms (Hot flashes/Night sweats) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Vasomotor symptoms (Hot flashes/Night sweats) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Vasomotor symptoms. The launch of emerging therapies will significantly impact the Vasomotor symptoms (Hot flashes/Night sweats) market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Vasomotor symptoms.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Vasomotor symptoms (Hot flashes/Night sweats) report Insights

  • Patient Population
  • Therapeutic Approaches
  • Vasomotor symptoms (Hot flashes/Night sweats) Pipeline Analysis
  • Vasomotor symptoms (Hot flashes/Night sweats) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Vasomotor symptoms (Hot flashes/Night sweats) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Vasomotor symptoms (Hot flashes/Night sweats) report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Vasomotor symptoms (Hot flashes/Night sweats) Market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Vasomotor symptoms (Hot flashes/Night sweats) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Vasomotor symptoms (Hot flashes/Night sweats)market Size during the forecast period (2017-2030)?
  • At what CAGR, the Vasomotor symptoms (Hot flashes/Night sweats) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Vasomotor symptoms (Hot flashes/Night sweats) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Vasomotor symptoms (Hot flashes/Night sweats) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Vasomotor symptoms?
  • What are the historical Vasomotor symptoms (Hot flashes/Night sweats) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Vasomotor symptoms (Hot flashes/Night sweats)in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Vasomotor symptoms?
  • Out of all 7MM countries, which country would have the highest Prevalent population of Vasomotor symptoms (Hot flashes/Night sweats) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Vasomotor symptoms (Hot flashes/Night sweats) along with the approved therapy?
  • What are the current treatment guidelines for treating Vasomotor symptoms (Hot flashes/Night sweats) in the USA, Europe, and Japan?
  • What are the Vasomotor symptoms (Hot flashes/Night sweats) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Vasomotor symptoms?
  • How many therapies are developed by each company for the treatment of Vasomotor symptoms?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Vasomotor symptoms?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vasomotor symptoms (Hot flashes/Night sweats) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Vasomotor symptoms (Hot flashes/Night sweats) and their status?
  • What are the key designations that have been granted for the emerging therapies for Vasomotor symptoms?
  • What are the global historical and forecasted market of Vasomotor symptoms?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Vasomotor symptoms (Hot flashes/Night sweats) market.
  • To understand the future market competition in the Vasomotor symptoms (Hot flashes/Night sweats) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Vasomotor symptoms (Hot flashes/Night sweats) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Vasomotor symptoms (Hot flashes/Night sweats) market.
  • To understand the future market competition in the Vasomotor symptoms (Hot flashes/Night sweats) market

Table of Contents

1. Key Insights

2. Vasomotor Symptoms (Hot Flashes/Night Sweats): Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2017
  • 2.2. Total Market Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Vasomotor Symptoms (VMS) associated with menopause: Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Vasomotor Symptoms (Hot Flashes/Night Sweats)
  • 6.3. Signs and Symptoms of VMS
  • 6.4. Pathophysiology of VMS
  • 6.5. Risk factors for VMS
  • 6.6. Effects of VMS
  • 6.7. Premature (early) Menopause
  • 6.8. Menopause Associated with Breast Cancer Treatment

7. Epidemiology and Patient Population

  • 7.1. Key Findings

8. Total Prevalent cases of Vasomotor Symptoms (Hot Flashes/Night Sweats) in Post-menopause in 7MM

9. Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause

  • 9.1. United States
    • 9.1.1. Assumptions and Rationale
    • 9.1.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in the United States
    • 9.1.3. Severity-specific cases of Hot Flashes in Post-menopause in the United States
  • 9.2. EU5 Countries
  • 9.3. Germany
    • 9.3.1. Assumptions and Rationale
    • 9.3.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Germany
    • 9.3.3. Severity-specific cases of Hot Flashes in Post-menopause in the Post-menopause in Germany
  • 9.4. France
    • 9.4.1. Assumptions and Rationale
    • 9.4.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in France
    • 9.4.3. Severity-specific cases of Hot Flashes in Post-menopause in the with Post-menopause in France
  • 9.5. Italy
    • 9.5.1. Assumptions and Rationale
    • 9.5.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Italy
    • 9.5.3. Severity-specific cases of Hot Flashes in Post-menopause in the Post-menopause in Italy
  • 9.6. Spain
    • 9.6.1. Assumptions and Rationale
    • 9.6.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Spain
    • 9.6.3. Severity-specific cases of Hot Flashes in Post-menopause in the Post-menopause in Spain
  • 9.7. The United Kingdom
    • 9.7.1. Assumptions and Rationale
    • 9.7.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in the UK
    • 9.7.3. Severity-specific cases of Hot Flashes in Post-menopause in the Post-menopause in the UK
  • 9.8. Japan
    • 9.8.1. Assumptions and Rationale
    • 9.8.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Japan
    • 9.8.3. Severity-specific cases of Hot Flashes in Post-menopause in the Post-menopause in Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices

  • 10.1. Hormonal Therapies
    • 10.1.1. Estrogen Replacement Therapies
    • 10.1.2. Progestational Agents
  • 10.2. Non-hormonal pharmacological treatments for vasomotor symptoms
    • 10.2.1. Clonidine
    • 10.2.2. Serotonin Reuptake Inhibitors
    • 10.2.3. Gabapentin
    • 10.2.4. Behavioral Modifications
  • 10.3. Complementary alternative medicines (CAM)

11. Unmet Needs

12. Marketed drugs by class

  • 12.1. Hormonal Therapies
    • 12.1.1. Estrogen Only Therapies
    • 12.1.2. Combination Therapies
  • 12.2. Non-Hormonal Therapies
    • 12.2.1. Approved Drug
    • 12.2.2. Off-Label Antidepressants
  • 12.3. Recent additions in Hormonal therapies
  • 12.4. Bijuva: TherapeuticsMD
    • 12.4.1. Drug Description
    • 12.4.2. Regulatory Milestones
    • 12.4.3. Other Development Activities
    • 12.4.4. Clinical Development
    • 12.4.5. Safety and Efficacy
    • 12.4.6. Product Profile

13. Emerging Therapies

  • 13.1. Key Cross Competition
  • 13.2. Hormonal Based therapies
  • 13.3. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)
    • 13.3.1. Product Description
    • 13.3.2. Other Developmental Activities
    • 13.3.3. Clinical Development
    • 13.3.4. Safety and Efficacy
    • 13.3.5. Product Profile
  • 13.4. Non-Hormonal Based therapies
  • 13.5. NT-814: KaNDy Therapeutics
    • 13.5.1. Product Description
    • 13.5.2. Other Developmental Activities
    • 13.5.3. Clinical Development
    • 13.5.4. Safety and Efficacy
    • 13.5.5. Product Profile
  • 13.6. FP-101: Fervent Pharmaceuticals
    • 13.6.1. Product Description
    • 13.6.2. Other Developmental Activities
    • 13.6.3. Clinical Development
    • 13.6.4. Safety and Efficacy
    • 13.6.5. Product Profile
  • 13.7. Fezolinetant: Astellas Pharma
    • 13.7.1. Drug Description
    • 13.7.2. Other Developmental Activities
    • 13.7.3. Clinical Development
    • 13.7.4. Safety and Efficacy
    • 13.7.5. Product Profile
  • 13.8. Other Potential therapies
  • 13.9. SJX 653: Sojournix
    • 13.9.1. Drug Description
    • 13.9.2. Other Developmental Activities
    • 13.9.3. Clinical Development
    • 13.9.4. Safety and Efficacy
    • 13.9.5. Product Profile
  • 13.10. MT-8554: Mitsubishi Tanabe Pharma
    • 13.10.1. Drug Description
    • 13.10.2. Clinical Development
    • 13.10.3. Product Profile

14. Hot Flashes: Seven Major Market Analysis

  • 14.1. Key Findings
  • 14.2. Market Size of Hot Flashes associated with Post Menopause in 7MM

15. Seven Major Market Outlook

  • 15.1. United States Market Size
    • 15.1.1. The total market size of Hot Flashes Associated with Post-menopause in the United States
    • 15.1.2. The total market size of Hot Flashes by Therapies in the United States
  • 15.2. Germany
    • 15.2.1. The total market size of Hot Flashes Associated with Post-menopause in Germany
    • 15.2.2. The total market size of Hot Flashes by Therapies in Germany
  • 15.3. France
    • 15.3.1. The total market size of Hot Flashes Associated with Post-menopause in France
    • 15.3.2. The total market size of Hot Flashes by Therapies in France
  • 15.4. Italy
    • 15.4.1. The total market size of Hot Flashes Associated with Post-menopause in Italy
    • 15.4.2. The total market size of Hot Flashes by Therapies in Italy
  • 15.5. Spain
    • 15.5.1. Total Market Size of Hot Flashes Associated with Post-menopause in Spain
    • 15.5.2. The total market size of Hot Flashes by Therapies in Spain
  • 15.6. United Kingdom
    • 15.6.1. The total market size of Hot Flashes Associated with Post-menopause in the United Kingdom
    • 15.6.2. The total market size of Hot Flashes by Therapies in the UK
  • 15.7. Japan
    • 15.7.1. The total market size of Hot Flashes in Japan
    • 15.7.2. The total market size of Hot Flashes by Therapies in Japan

16. Market Drivers

17. Market Barriers

18. SWOT

19. Case Studies

  • 19.1. A Case Report of Hot Flashes for Menopause Awareness
  • 19.2. A Case Report of a symptomatic patient in whom hormone therapy (HT) was abruptly stopped

20. KOL Views

21. Appendix

  • 21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

  • Table 1 Conditions that may cause or mimic vasomotor events and that can be distinguished from menopausal symptoms by history, examination, and investigations
  • Table 2 Total Prevalent cases of Vasomotor Symptoms (Hot Flashes) in Post-menopause in 7MM (2017-2030)
  • Table 3 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the United States (2017-2030)
  • Table 4 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post menopause in the United States (2017-2030)
  • Table 5 Total Prevalent Population of Hot Flashes associated with Post Menopause in Germany (2017-2030)
  • Table 6 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Germany (2017-2030)
  • Table 7 Total Prevalent Population of Hot Flashes Associated with Post-menopause in France (2017-2030)
  • Table 8 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in France (2017-2030)
  • Table 9 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Italy (2017-2030)
  • Table 10 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017-2030)
  • Table 11 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Table 12 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Table 13 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Table 14 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Table 15 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Japan (2017-2030)
  • Table 16 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017-2030)
  • Table 17 Hot Flashes Treatments Algorithm
  • Table 18 Complementary and alternative medicines for the treatment of menopausal symptoms
  • Table 19 Key cross of Estrogen-based Oral therapies
  • Table 20 Key cross of Estrogen-based Transdemal Patch
  • Table 21 key cross of Estrogen-based Transdemal Spray
  • Table 22 key cross of Estrogen-based Transdemal gel
  • Table 23 key cross of Estrogen-based Vaginal Ring
  • Table 24 Key cross of Oral combination therapies
  • Table 25 Key cross of Transdermal combination therapies
  • Table 26 Details of Non-Hormonal therapies
  • Table 27 Details of off-label Antidepressant therapies
  • Table 28 Donesta, Clinical Trial Description, 2020
  • Table 29 NT-814, Clinical Trial Description, 2020
  • Table 30 FP-101, Clinical Trial Description, 2020
  • Table 31 Fezolinetant, Clinical Trial Description, 2020
  • Table 32 MT-8554, Clinical Trial Description, 2020
  • Table 33 Market Size of Hot Flashes associated with Post Menopause in 7MM in USD Million (2017-2030)
  • Table 34 US Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)
  • Table 35 US Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)
  • Table 36 Market Size of Hot Flashes associated with Post-menopause in Germany, USD Millions (2017-2030)
  • Table 37 Germany Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)
  • Table 38 Market Size of Hot Flashes associated with Postmenopause in France, USD Millions (2017-2030)
  • Table 39 France Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)
  • Table 40 Market Size of Hot Flashes associated with Post menopause in Italy, USD Millions (2017-2030)
  • Table 41 Italy Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)
  • Table 42 Market Size of Hot Flashes associated with Post Menopause in Spain, USD Millions (2017-2030)
  • Table 43 Spain Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)
  • Table 44 Market Size of Hot Flashes associated with Post Menopause in the UK, USD Millions (2017-2030)
  • Table 45 UK Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)
  • Table 46 Market Size of Hot Flashes associated with Post Menopause in Japan, USD Millions (2017-2030)
  • Table 47 Japan Market Size of Hot Flashes associated with Post-menopause in USD Million (2017-2030)

List of Figures

  • Figure 1 Epidemiology and Market Methodology
  • Figure 2 Stages of menopause
  • Figure 3 Vasomotor Symptoms
  • Figure 4 The three major components involved in the thermoregulatory function
  • Figure 5 Relationship between estrogen and a woman's reproductive phases and the occurrence of hot flashes
  • Figure 6 Maintenance of core body temperature (CBT) is critical to organ integrity and optimal function.
  • Figure 7 Relationship between estrogen and a woman's reproductive phases and the occurrence of hot flashes
  • Figure 8 Risk factors for VMS
  • Figure 9 Effects of VMS
  • Figure 10 Impact of VMS on QOL
  • Figure 11 Breast Cancer therapies causing Menopause
  • Figure 12 Total Prevalent cases of Vasomotor Symptoms (Hot Flashes) in Post-menopause in 7MM (2017-2030)
  • Figure 13 Prevalence of Hot Flashes Associated with Post menopause in the United States (2017-2030)
  • Figure 14 Severity-specificSeverity-specific Prevalence of Hot Flashes associated with Post-menopause in the US (2017-2030)
  • Figure 15 Prevalence of Hot Flashes associated with Post Menopause in Germany (2017-2030)
  • Figure 16 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Germany (2017-2030)
  • Figure 17 Prevalence of Hot Flashes Associated with Post-menopause in France (2017-2030)
  • Figure 18 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in France (2017-2030)
  • Figure 19 Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017-2030)
  • Figure 20 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017-2030)
  • Figure 21 Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Figure 22 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Figure 23 Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Figure 24 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Figure 25 Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017-2030)
  • Figure 26 Severity-specificSeverity-specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017-2030)
  • Figure 27 Non-hormonal pharmacological treatments for vasomotor symptoms
  • Figure 28 Unmet Needs of Hot Flashes
  • Figure 29 Market Size of Hot Flashes associated with post menopause in USD Million (2017-2030)
  • Figure 30 Market Size of Hot Flashes associated with Post-menopause in the US, USD Millions (2017-2030)
  • Figure 31 Market Size of Hot Flashes associated with Post-menopause in the US by therapies, USD Millions (2017-2030)
  • Figure 32 Market Size of Hot Flashes associated with Post-menopause in Germany, USD Millions (2017-2030)
  • Figure 33 Market Size of Hot Flashes associated with Post-menopause in Germany by therapies, USD Millions (2017-2030)
  • Figure 34 Market Size of Hot Flashes associated with Post-menopause in France, USD Millions (2017-2030)
  • Figure 35 Market Size of Hot Flashes associated with Post-menopause in France by therapies, USD Millions (2017-2030)
  • Figure 36 Market Size of Hot Flashes associated with Post menopause in Italy, USD Millions (2017-2030)
  • Figure 37 Market Size of Hot Flashes associated with Post-menopause in Italy by therapies, USD Millions (2017-2030)
  • Figure 38 Market Size of Hot Flashes associated with Post Menopause in Spain, USD Millions (2017-2030)
  • Figure 39 Market Size of Hot Flashes associated with Post-menopause in Spain by therapies, USD Millions (2017-2030)
  • Figure 40 Market Size of Hot Flashes associated with Post Menopause in the UK, USD Millions (2017-2030)
  • Figure 41 Market Size of Hot Flashes associated with Post-menopause in the UK by therapies, USD Millions (2017-2030)
  • Figure 42 Market Size of Hot Flashes associated with Post Menopause in Japan, USD Millions (2017-2030)
  • Figure 43 Market Size of Hot Flashes associated with Post-menopause in Japan by therapies, USD Millions (2017-2030)
  • Figure 44 Market Drivers
  • Figure 45 Market Barriers